Pediatric Nephrology

, Volume 24, Issue 7, pp 1321–1328

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children

  • Koichi Kamei
  • Shuichi Ito
  • Kandai Nozu
  • Shuichiro Fujinaga
  • Makiko Nakayama
  • Mayumi Sako
  • Mari Saito
  • Maki Yoneko
  • Kazumoto Iijima
Original Article

Abstract

We conducted a multicenter prospective trial to evaluate the efficacy, safety and pharmacokinetics of a single dose of rituximab (375 mg/m2 body surface area) for the treatment of children with refractory steroid-dependent nephrotic syndrome (SDNS). All patients (n = 12) were able to discontinue steroids at a median of 74 days after treatment. The frequency of relapses per 6 months was significantly reduced and the steroid-free period per 6 months was significantly increased after treatment compared with those before treatment. The condition in nine of the patients (75%) relapsed at a median of 129 days after treatment, and seven patients were given additional rituximab due to steroid dependency. Most of the relapses developed simultaneously with recovery of B-cells. However, three patients (25%) did not have a relapse with B-cell recovery and the disease was kept in remission for more than 1 year. None of the patients developed life-threatening adverse events. This is the first report of a prospective study of a single dose of rituximab for refractory SDNS. Treatment with a single dose of rituximab may be effective for refractory SDNS, but its efficacy to prevent relapses was transient in most of the patients.

Keywords

Refractory steroid-dependent nephrotic syndrome Children Clinical trial Rituximab Pharmacokinetics 

References

  1. 1.
    Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N (2002) Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 61:1801–1805PubMedCrossRefGoogle Scholar
  2. 2.
    Kranz B, Vester U, Büscher R, Wingen AM, Hoyer PF (2008) Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Pediatr Nephrol 23:581–586PubMedCrossRefGoogle Scholar
  3. 3.
    Benz K, Dötsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794–797PubMedCrossRefGoogle Scholar
  4. 4.
    Gilbert RD, Hulse E, Rigden S (2006) Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 21:1698–1700PubMedCrossRefGoogle Scholar
  5. 5.
    François H, Daugas E, Bensman A, Ronco P (2007) Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 49:158–161PubMedCrossRefGoogle Scholar
  6. 6.
    Smith GC (2007) Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol 22:893–898PubMedCrossRefGoogle Scholar
  7. 7.
    Kemper MJ, Möller K, Ludwig K, Rink N, Muller-Wiefel DE (2006) Rituximab in the treatment of refractory steroid-sensitive nephrotic syndrome (abstract). Pediatr Nephrol 21:1528Google Scholar
  8. 8.
    Dallachio IA, Trimoreau F, Feuillard J, Guigoinis V (2006) A case of steroid-dependent nephrotic syndrome treated with rituximab (abstract). Pediatr Nephrol 21:1615Google Scholar
  9. 9.
    Hofstra JM, Deegens JK, Wetzels JF (2007) Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol Dial Transplant 22:2100–2102PubMedCrossRefGoogle Scholar
  10. 10.
    Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:269–279CrossRefGoogle Scholar
  11. 11.
    Bagga A, Sinha A, Moudgil A (2007) Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 356:2751–2752PubMedCrossRefGoogle Scholar
  12. 12.
    Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, Iijima K (2008) Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 23:481–485PubMedCrossRefGoogle Scholar
  13. 13.
    Yang T, Nast CC, Vo A, Jordan SC (2008) Rapid remission of steroid and mycophenolate mofetil (MMF)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant 23:377–380PubMedCrossRefGoogle Scholar
  14. 14.
    Suri M, Tran K, Sharma AP, Filler G, Grimmer J (2008) Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol 40:807–810PubMedCrossRefGoogle Scholar
  15. 15.
    Tabata K, Yamaoka K, Kaibara A, Suzuki S, Terakawa M, Hata T (1999) Moment analysis program available on Microsoft Excel. Xenobiot Metab Dispos 14:286–293Google Scholar
  16. 16.
    Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, Roggero AL, Fineberg NS, Taber T, Kraus MA, Pescovitz MD (2004) Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77:542–548PubMedCrossRefGoogle Scholar
  17. 17.
    Berinstein NL, Grillo-López AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D (1998) Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 9:995–1001PubMedCrossRefGoogle Scholar
  18. 18.
    Davis TA, Maloney DG, Grillo-López AJ, White CA, Williams ME, Weiner GJ, Dowden S, Levy R (2000) Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 6:2644–2652PubMedGoogle Scholar
  19. 19.
    Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, Ohtsu T, Igarashi T, Sasaki Y, Kinoshita T, Murate T (1998) Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 9:527–534PubMedCrossRefGoogle Scholar
  20. 20.
    Iacona I, Lazzarino M, Avanzini MA, Rupolo M, Arcaini L, Astori C, Lunghi F, Orlandi E, Morra E, Zagonel V, Regazzi MB (2000) Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 22:295–301PubMedCrossRefGoogle Scholar
  21. 21.
    Regazzi MB, Iacona I, Avanzini MA, Rupolo M, Arcaini L, Astori C, Lunghi F, Orlandi E, Morra E, Zagonel V, Regazzi MB (2005) Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit 27:785–792PubMedCrossRefGoogle Scholar
  22. 22.
    Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE (2007) Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 47:1119–1128PubMedCrossRefGoogle Scholar
  23. 23.
    Kemper MJ, Meyer-Jark T, Lilova M, Müller-Wiefel DE (2003) Combined B- and T-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol 60:242–247PubMedGoogle Scholar
  24. 24.
    Cho BS, Yoon SR, Jang JY, Pyun KH, Lee CE (1999) Up-regulation of interleukin-4 and CD23/FcepsilonRII in minimal change nephrotic syndrome. Pediatr Nephrol 13:199–204PubMedCrossRefGoogle Scholar
  25. 25.
    Kimata H, Fujimoto M, Furusho K (1995) Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome. Eur J Immunol 25:1497–1450PubMedCrossRefGoogle Scholar
  26. 26.
    Martin F, Chan AC (2004) Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20:517–527PubMedCrossRefGoogle Scholar
  27. 27.
    Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, Tsujimura S, Nawata M, Iwata S, Azuma T, Mimori T, Tanaka Y (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470–475PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2009

Authors and Affiliations

  • Koichi Kamei
    • 1
    • 2
  • Shuichi Ito
    • 1
    • 3
  • Kandai Nozu
    • 4
  • Shuichiro Fujinaga
    • 5
  • Makiko Nakayama
    • 1
  • Mayumi Sako
    • 1
  • Mari Saito
    • 6
  • Maki Yoneko
    • 7
  • Kazumoto Iijima
    • 1
    • 8
  1. 1.Department of NephrologyNational Center for Child Health and DevelopmentTokyoJapan
  2. 2.Department of Pediatrics and Developmental BiologyTokyo Medical and Dental UniversityTokyoJapan
  3. 3.Department of PediatricsYokohama City University Medial CenterYokohamaJapan
  4. 4.Department of PediatricsKobe University Graduate School of MedicineKobeJapan
  5. 5.Department of NephrologySaitama Children’s Medical CenterSaitamaJapan
  6. 6.Biostatistics/Epidemiology and Preventive Health Sciences, School of Health Science and NursingUniversity of TokyoTokyoJapan
  7. 7.Division of Clinical ResearchNational Center for Child Health and DevelopmentTokyoJapan
  8. 8.Division of Child Health and Development, Department of PediatricsKobe University Graduate School of MedicineKobeJapan

Personalised recommendations